Press Release Details

Cerus Corporation to Webcast Second Quarter Financial Results Conference Call

July, 26 2005

CONCORD, Calif.--(BUSINESS WIRE)--July 26, 2005--In conjunction with Cerus Corporation's (Nasdaq:CERS) report of its second quarter financial results, a live webcast will be made of its conference call hosted by Claes Glassell, president and CEO, William J. Dawson, vice president, finance and CFO, Larry M. Corash, vice president and chief medical officer, and David N. Cook, vice president, research and development.

    What:     Financial results, with an update on progress and future
              outlook

    When:     Tuesday, August 2, 2005 at 4:30 p.m. ET

    Where:    http://www.cerus.com

    Contact:  Ruey-Li Hwang / Cerus Corporation, 925-288-6017

Cerus Corporation's second quarter release will be issued on August 2, 2005 at 4:00 p.m. EDT and will be made available at http://www.cerus.com. The company will archive the earnings release audio replay as well as the press release on the company's website.

The conference call is protected by copyright. It cannot be recorded or rebroadcast without Cerus' permission.

About Cerus Corporation

Cerus Corporation is developing novel products for cancer, infectious disease and blood safety based on multiple, innovative technology platforms. The company is building a pipeline of next generation cancer immunotherapies by combining its proprietary attenuated Listeria vector platform with promising disease antigens. These products are designed to stimulate innate and T cell immune pathways, generating highly potent anti-tumor responses. Cerus is applying its Helinx technology to develop the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen inactivation. The company's strategy is to leverage the broad potential of its technologies and products through alliances. Cerus' partners to date include MedImmune and Johns Hopkins University for cancer immunotherapy, and Baxter International and BioOne for the INTERCEPT Blood System.

Helinx is a trademark of Cerus Corporation.

Baxter and INTERCEPT are trademarks of Baxter International Inc.


    CONTACT: Cerus Corporation
             Ruey-Li Hwang, 925-288-6017

    SOURCE: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600